Screener
Cartesian Therapeutics, Inc. RNAC Q4 2025 Annual earnings
Reported March 9, 2026 · Before market open
Revenue$947.0KBeat by $796.7K
EPS-$1.38Miss by $0.56
Revenue estimate$150.3K
EPS estimate-$0.82
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$180.0K
EPS estimate-$1.02
Versus estimates
Revenue
Q1 2026$78.0KMiss by $141.8K
Q4 2025$947.0KBeat by $796.7K
Q3 2025$452.0KBeat by $351.8KQ2 2025$298.0KBeat by $120.4KQ1 2025$1.1MBeat by $412.5KDiluted EPS
FAQ
- When did Cartesian Therapeutics, Inc. report Q4 2025 earnings?
- Cartesian Therapeutics, Inc. (RNAC) reported Q4 2025 earnings on March 9, 2026 before market open.
- What were Cartesian Therapeutics, Inc.'s Q4 2025 revenue and EPS?
- Cartesian Therapeutics, Inc. reported revenue of $947.0K and eps of $-1.38 for Q4 2025.
- Did Cartesian Therapeutics, Inc. beat estimates in Q4 2025?
- Revenue beat the consensus estimate of $150.3K by $796.7K. EPS missed the consensus estimate of $-0.82 by $0.56.
- How did Cartesian Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 24.8% from $759.0K a year earlier and eps declined 133.9% from $-0.59.
- Where can I find Cartesian Therapeutics, Inc.'s Q4 2025 SEC filings?
- You can read the 8-K earnings release (0001453687-26-000063) and the 10-K periodic report (0001453687-26-000064) directly on SEC EDGAR. The filing index links above go to sec.gov.
